RV-PA uncoupling is associated with increased mortality in transthyretin amyloid cardiomyopathy treated with tafamidis
Clinical Research in Cardiology · 2026-12 · 115 (12) · 2141-2151
DOI: 10.1007/s00392-024-02576-2 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Research in Cardiology, online erschienen am 20.11.2024. Verfasst von Stéphanie K Schwarting und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine I, LMU University Hospital Munich, Marchioninistrasse 15, 81377, Munich, Germany. Stephanie.Bieber@med.uni-muenchen.de. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Cardiomyopathies, Benzoxazoles, Pulmonary Artery. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Klinikum der Universität München.
Abstract (Originalsprache)
Background
The right ventricle to pulmonary artery coupling (RV-PAc) describes the right ventricle’s ability to adjust to an increased afterload. In case of transthyretin amyloid cardiomyopathy (ATTR-CM), impaired RV-PAc can result from increased left ventricular diastolic stiffness due to fibril deposition.
Objectives
While RV-PAc is a validated prognostic parameter in pulmonary arterial hypertension (PAH), its prognostic relevance in ATTR-CM remains unknown. We sought to evaluate the prognostic implications of impaired RV-PAc on survival in ATTR-CM.
Methods
In this multicentre study, RV-PAc was investigated by the echocardiographic surrogate of ratio of tricuspid annular plane systolic excursion to estimated pulmonary arterial systolic pressure (TAPSE/PASP) in 418 ATTR-CM patients, all treated with a TTR stabilizer. The primary outcome was all-cause mortality.
Results
Within a median time of 1.52 [IQR 0.72–2.56] years after diagnosis, 49 (11.7%) patients died. In multivariate Cox regression analysis impaired RV-PAc was a strong independent predictor of mortality (Hazard Ratio (HR) 2.16, 95% Confidence Interval (CI) 1.14–4.07, p = 0.018). RV-PAc ratio at first presentation emerged as a robust marker for risk stratification with a determined optimal cut-off of 0.382 mm/mmHg (area under the curve (AUC) 0.73, 95% CI 0.65–0.81). Patients with RV-PAc ratio ≤ 0.382 mm/mmHg exhibited significantly lower survival (HR 4.17, 95% CI 2.21–7.87, p < 0.001) within 3 years of follow up than those with RV-PAc ratio above the cut-off (Graphical Abstract).
Conclusion
Impaired adaptation of the RV to increased afterload is associated with worse outcome in ATTR-CM patients. RV-PAc ratio can serve as an echocardiographic predictor for all-cause mortality. Therefore, the determination of RV-PAc could improve risk stratification for ATTR-CM patients. Graphical Abstract RV-PA coupling in ATTR-CM patients. This two-center study included patients with transthyretin cardiomyopathy, all treated with specific stabilizer. Tricuspid annular plane systolic excursion (TAPSE, green arrow) to systolic pulmonary artery pressure (PASP, light purple arrows) ratio was investigated retrospectively as correlate for rightventricle to pulmonary artery coupling (RV-PAc). Impaired RV-PAc was associated with higher risk for all-cause mortality, reduced left ventricular function and advanced stages of disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine I, LMU University Hospital Munich, Marchioninistrasse 15, 81377, Munich, Germany. Stephanie.Bieber@med.uni-muenchen.de.
- Department of Cardiology, Angiology and Respiratory Medicine, University Hospital of Heidelberg, Im Neuenheimer Feld 410, Heidelberg, Germany. Stephanie.Bieber@med.uni-muenchen.de.
- Department of Cardiology, Angiology and Respiratory Medicine, University Hospital of Heidelberg, Im Neuenheimer Feld 410, Heidelberg, Germany.
- Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.
- Department of Medicine I, LMU University Hospital Munich, Marchioninistrasse 15, 81377, Munich, Germany.
- Department of Internal Medicine V, University Hospital of Heidelberg, Im Neuenheimer Feld 410, Heidelberg, Germany.
Förderung
- Klinikum der Universität München
Zitieren
APA
Schwarting, S. K., Poledniczek, M., Metodiev, Y., Stolz, L., Hofmann, E., Hegenbart, U., Schönland, S., Kääb, S., Massberg, S., Frey, N., & Aus dem Siepen, F. (2026). RV-PA uncoupling is associated with increased mortality in transthyretin amyloid cardiomyopathy treated with tafamidis. Clinical Research in Cardiology, 115(12), 2141-2151. https://doi.org/10.1007/s00392-024-02576-2
Vancouver
Schwarting SK, Poledniczek M, Metodiev Y, Stolz L, Hofmann E, Hegenbart U, et al. RV-PA uncoupling is associated with increased mortality in transthyretin amyloid cardiomyopathy treated with tafamidis. Clinical Research in Cardiology. 2026;115(12):2141-2151. doi:10.1007/s00392-024-02576-2
BibTeX
@article{Schwarting2026,
author = {Schwarting, Stéphanie K and Poledniczek, Michael and Metodiev, Yuliyan and Stolz, Lukas and Hofmann, Eva and Hegenbart, Ute and Schönland, Stefan and Kääb, Stefan and Massberg, Steffen and Frey, Norbert and Aus dem Siepen, Fabian},
title = {RV-PA uncoupling is associated with increased mortality in transthyretin amyloid cardiomyopathy treated with tafamidis},
journal = {Clinical Research in Cardiology},
year = {2026},
volume = {115},
number = {12},
pages = {2141--2151},
doi = {10.1007/s00392-024-02576-2}
}
EUVIMED